Medicines for Malaria Venture (MMV) Joins The Pool for Open Innovation Against Neglected Tropical Diseases
Global Health Progress supports MMV's decision to contribute its intellectual property.

WASHINGTON, DC, September 04, 2010 /24-7PressRelease/ -- Global Health Progress (GHP) is pleased to highlight the announcement that the not-for-profit public-private partnership Medicines for Malaria Venture (MMV) will became the first product development partnership (PDP) to contribute intellectual property to The Pool for Open Innovation against Neglected Tropical Diseases (The Pool).

MMV joined GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology (MIT) in providing intellectual property to The Pool. Discussing the decision, Professor Patrick Nef, Executive Vice President of Business Development at MMV, states, "In this way we hope to make fully available the know-how and technologies, assembled by MMV against malaria, for the research and development of innovative and efficacious treatments for other neglected diseases."

By emphasizing a more accessible approach to intellectual property and know-how, The Pool facilitates access to patents and/or technologies for organizations that want to conduct research on treatments and motivates innovative and efficient drug discoveries and developments for other neglected diseases.

The Pool is administered by BIO Ventures for Global Health (BVGH). It's accessible to industry, non-profit institutions, and academic researchers who conduct research and drug development activities that deliver real benefits for patients in the least developed countries of the world.

Global Health Progress echoes the sentiment that MMV's contribution of patents to The Pool, resulting from its research for new antimalarials, is an important milestone from an organization that plays a major role in leading the development of new therapeutics for malaria.

Global Health Progress supports the continuing partnership between not-for-profit public-private partnerships and research-based biopharmaceutical companies as a way to fight neglected tropical diseases through targeted research and development (R&D), improving access to critical medicines and providing key intellectual property.

Press Release Contact Information:

Mark Grayson
Global Health Progress
Global Health Progress
950 F Street, N.W. Suite 300
Washington, DC
United States 20004
Voice: (202) 835-3460
Website: Visit Our Website